

Fig. 1 Anti-PT Results

2/10




Fig. 2 Anti-FHA Results

3/10




Fig. 3 Anti-PRN Results

4/10




Fig.4 Anti-PT Results
Pre- and Post-Serum Antibody Responses Following Immunization
With SB "Monovalent" Pa - AAPT, 1996

5/10




Fig. 5 Anti-FHA Results
Pre-and Post-Serum Antibody Responses (Cont.) AAPT, 1996

6/10




Fig. 6 Anti-PRN Results
Pre-and Post-Serum Antibody Responses (Cont.) AAPT, 1996

7/10

Pain	dtpa	dT
≤ 48 h	58	60
15 days	60	60
Severe	0	0
Redness		
≤ 48 h	30	37
15 days	30	37
> 20 MM	17	20
Swelling		
≤ 48 h	30	37
15 days	30	37
> 20MM	5	8.3
Fever		
≤ 48 h	7	7
15 days	8	8
> 39°C	0	0

Fig. 7 % Reporting
dtpa 005 - Reactogenicity

Anti-D	dtpa	dT
Pre		
≥ 0.1	44%	44%
Post		
≥ 0.1	80%	78%
GMT	0.85	0.81
Anti-T		
Pre		
≥ 0.1	88%	88%
Post		
≥ 0.1	97%	100%
GMT	7.37	13.6

Fig. 8 dtpa 005
SUBSTITUTE SHEET (RULE 26)

F099040" 58422860

8/10

	Pain Week1	Moderate Pain Week 1	Erythema Week 1	Pain Weeks 2-4	Erythema Weeks 2-4
SB-Med (N=31)	90	10	10	17	3
Placebo (N=31)	19	3	3	3	0

- No serious adverse events
- No severe pain
- 2 subjects with hives (days 1-4; days 18-22)

Fig. 9 % Reporting
AAPT- Reactogenicity

Pain	dtpa	dT
≤ 48 h	69	70
15 days	69	70
Severe	0	1
Redness		
≤ 48 h	12	20
15 days	12	20
> 30 MM	1	9
Swelling		
≤ 48 h	12	28
15 days	13	30
> 30MM	7	15
Fever		
≤ 48 h	5	6
15 days	13	15
> 39°C	0	1


Fig. 10 % Reporting
dtpa 003 - Reactogenicity
SUBSTITUTE SHEET (RULE 26)

T09040" 58/22860

9/10

Anti-D	dtpa	dT
Pre		
≥ 0.1	72%	72%
Post		
≥ 0.1	100%	100%
GMT	3.3	10.5

Anti-T		
Pre		
≥ 0.1	94%	99%
Post		
≥ 0.1	100%	100%
GMT	22.9	54.5

Fig. 11 Antibody responses dtpa 003**Fig. 12** Anti-PT Results
SUBSTITUTE SHEET (RULE 26)




Fig. 13 Anti-FHA Results




Fig. 14 Anti-PRN Results
SUBSTITUTE SHEET (RULE 26)